O&G Vivas · Antenatal care — fetal medicine
Fetal anaemia and hydrops fetalis — structured oral station (12 minutes)
FRANZCOG oral-format station on non-immune hydrops: candidate confirms the diagnosis, splits the differential by the antibody screen, lays out the SMFM 7 workup and MCA-PSV surveillance, describes intrauterine transfusion and treatable-cause management, and counsels honestly. Scored against the eight published RANZCOG oral domains.
On this page & tools
Target exams
Station format
4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply to every station: history and examination; investigations and interpreting results; treatment and management; clinical knowledge; complex, urgent or unusual clinical presentations; rapport with patient, support person or colleague; respect; communication skills. You are being marked on how you behave, not only what you know. [1]
Reveal the examiner script and model responses
Opening prompt — "You are shown a hydropic fetus at 21 weeks with a negative antibody screen. Talk me through your approach."
Model response — say it in this order: [1]
- "This is non-immune hydrops — two or more fluid collections with a negative antibody screen. Hydrops is an endpoint, not a diagnosis, so I will work systematically to find the cause before any decision on viability."
- "Several non-immune causes are treatable — arrhythmia, anaemia, hydrothorax — so I will not assume the worst."[1]
Examiner is listening for: the endpoint-not-diagnosis framing, and the antibody-screen branch. [1]
Probe 1 — "What is your differential and how will you investigate it?"
- "The SMFM #7 categories of non-immune hydrops, in order of frequency: cardiovascular (structural and arrhythmia), chromosomal, haematological, structural anomaly, monochorionic twin complications, infection, and placental causes."
- "Workup: detailed anomaly scan and echocardiography, fetal karyotype and chromosomal microarray regardless of anomaly, maternal infection screen (parvovirus B19 IgG/IgM and PCR, CMV, syphilis, toxoplasma), and middle cerebral artery peak systolic velocity to detect anaemia."[1]
Probe 2 — "Why do you measure MCA-PSV in a hydropic fetus?"
- "Because anaemia of any cause drives much of hydrops. In the anaemic fetus, blood viscosity falls and cardiac output rises, so the velocity in the middle cerebral artery increases."
- "Mari's 2000 New England Journal study showed an increased MCA-PSV detected moderate or severe anaemia with a sensitivity of 100 percent (95 percent confidence interval 86 to 100 percent) and a false-positive rate of 12 percent."
- "The action threshold is an MCA-PSV above 1.5 multiples of the median — that triggers fetal blood sampling with intrauterine transfusion readiness."[2][3]
Probe 3 — "The fetal heart shows supraventricular tachycardia. How does that change your management?"
- "This is a treatable cause — arrhythmia is one of the leading non-immune categories. I would start transplacental therapy, most commonly digoxin, with sotalol or flecainide as alternatives, to restore sinus rhythm. Hydrops often resolves once the rhythm is controlled."
- "I would also continue the rest of the workup, because more than one cause can coexist."[1]
Probe 4 — "If this were a parvovirus infection instead, how would the anaemia differ and how would you manage it?"
- "Parvovirus causes anaemia by erythroid aplasia, not haemolysis — the virus has a tropism for erythroid progenitors and arrests erythropoiesis."
- "I would monitor with serial MCA-PSV for weeks after infection, and transfuse intrauterinely for severe anaemia; intravenous immunoglobulin has a role in selected cases."
- "Survival with appropriate intrauterine transfusion is good; untreated hydropic parvovirus has high mortality."[1][4]
Probe 5 — "How do you counsel the woman about prognosis?"
This is a scored domain — speak to it out loud: [1]
- "Prognosis depends entirely on the cause. A treatable arrhythmia or anaemia can resolve completely. A lethal chromosomal cause carries near-total mortality."
- "I would be honest about the uncertainty, explain the plan and the timeline, and offer to involve the fetal medicine and neonatal teams and, where appropriate, palliative care."
- "I would give written information and a named contact, and acknowledge her fear."[1]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship atlas.
References4Show ledgerHide ledger
- [1]Norton ME, Chauhan SP, Dashe JS Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #7: nonimmune hydrops fetalis Am J Obstet Gynecol, 2015.PMID 25557883
- [2]Mari G, Norton ME, Stone J, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia—diagnosis and management Am J Obstet Gynecol, 2015.PMID 25824811
- [3]Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses N Engl J Med, 2000.PMID 10620643
- [4]Moise KJ Jr Management of rhesus alloimmunization in pregnancy Obstet Gynecol, 2008.PMID 18591322